MERTK as a novel therapeutic target in head and neck cancer

被引：20

作者：

von Maessenhausen, Anne ^{[1
,2
,3
]}

Sanders, Christine ^{[1
,2
,3
]}

Thewes, Britta ^{[1
,2
,3
]}

Deng, Mario ^{[4
,5
,6
,7
]}

Queisser, Angela ^{[1
,2
,3
]}

Vogel, Wenzel ^{[4
,5
,6
,7
]}

Kristiansen, Glen ^{[2
,3
]}

Duensing, Stefan ^{[8
]}

Schroeck, Andreas ^{[3
,9
]}

Bootz, Friedrich ^{[3
,9
]}

Brossart, Peter ^{[3
,10
]}

Kirfel, Jutta ^{[2
,3
]}

Heasley, Lynn ^{[11
]}

Braegelmann, Johannes ^{[1
,3
,10
]}

Perner, Sven ^{[4
,5
,6
,7
]}

机构：

[1] Univ Hosp Bonn, Sect Prostate Canc Res, Bonn, Germany

[2] Univ Hosp Bonn, Inst Pathol, Bonn, Germany

[3] Univ Hosp Bonn, Ctr Integrated Oncol Cologne Bonn, Bonn, Germany

[4] Univ Hosp Luebeck, Pathol, Lubeck, Germany

[5] Leibniz Res Ctr Borstel, Lubeck, Germany

[6] Univ Hosp Luebeck, Pathol, Borstel, Germany

[7] Leibniz Res Ctr Borstel, Borstel, Germany

[8] Heidelberg Univ, Dept Urol, Heidelberg, Germany

[9] Univ Hosp Bonn, Dept Otorhinolaryngol Head & Neck Surg, Bonn, Germany

[10] Univ Hosp Bonn, Dept Hematol Oncol, Bonn, Germany

[11] Univ Colorado, Dept Craniofacial Biol, Anschutz Med Campus, Aurora, CO USA

来源：

ONCOTARGET | 2016年 / 7卷 / 22期

关键词：

head and neck cancer; MERTK; targeted therapy; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; COPY NUMBER; INHIBITION; EXPRESSION; MODELS; OVEREXPRESSION; AMPLIFICATION; RADIOTHERAPY;

D O I：

10.18632/oncotarget.8724

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although head and neck cancer (HNSCC) is the sixth most common tumor entity worldwide therapy options remain limited leading to 5-year survival rates of only 50 %. MERTK is a promising therapeutic target in several tumor entities, however, its role in HNSCC has not been described yet. The aim of our study was to investigate the biological significance of MERTK and to evaluate its potential as a novel therapeutic target in this dismal tumor entity. In two large HNSCC cohorts (n=537 and n=520) we found that MERTK is overexpressed in one third of patients. In-vitro, MERTK overexpression led to increased proliferation, migration and invasion whereas MERTK inhibition with the small molecule inhibitor UNC1062 or MERTK knockdown reduced cell motility via the small GTPase RhoA. Taken together, we are the first to show that MERTK is frequently overexpressed in HNSCC and plays an important role in tumor cell motility. It might therefore be a potential target for selected patients suffering from this dismal tumor entity.

引用

页码：32678 / 32694

页数：17

共 50 条

[1] Motility-related proteins as markers for head and neck squamous cell cancer [J].

Abraham, MT ;

Kuriakose, MA ;

Sacks, PG ;

Yee, H ;

Chiriboga, L ;

Bearer, EL ;

Delacure, MD .

LARYNGOSCOPE, 2001, 111 (07) :1285-1289

[2] Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 [J].

Agrawal, Nishant ;

Frederick, Mitchell J. ;

Pickering, Curtis R. ;

Bettegowda, Chetan ;

Chang, Kyle ;

Li, Ryan J. ;

Fakhry, Carole ;

Xie, Tong-Xin ;

Zhang, Jiexin ;

Wang, Jing ;

Zhang, Nianxiang ;

El-Naggar, Adel K. ;

Jasser, Samar A. ;

Weinstein, John N. ;

Trevino, Lisa ;

Drummond, Jennifer A. ;

Muzny, Donna M. ;

Wu, Yuanqing ;

Wood, Laura D. ;

Hruban, Ralph H. ;

Westra, William H. ;

Koch, Wayne M. ;

Califano, Joseph A. ;

Gibbs, Richard A. ;

Sidransky, David ;

Vogelstein, Bert ;

Velculescu, Victor E. ;

Papadopoulos, Nickolas ;

Wheeler, David A. ;

Kinzler, Kenneth W. ;

Myers, Jeffrey N. .

SCIENCE, 2011, 333 (6046) :1154-1157

[3] Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522 [J].

Ang, K. Kian ;

Zhang, Qiang ;

Rosenthal, David I. ;

Nguyen-Tan, Phuc Felix ;

Sherman, Eric J. ;

Weber, Randal S. ;

Galvin, James M. ;

Bonner, James A. ;

Harris, Jonathan ;

El-Naggar, Adel K. ;

Gillison, Maura L. ;

Jordan, Richard C. ;

Konski, Andre A. ;

Thorstad, Wade L. ;

Trotti, Andy ;

Beitler, Jonathan J. ;

Garden, Adam S. ;

Spanos, William J. ;

Yom, Sue S. ;

Axelrod, Rita S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2940-+

[4]

Ang KK, 2002, CANCER RES, V62, P7350

[5]

[Anonymous], R LANG ENV STAT COMP

[6] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[7] Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase Cε-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells [J].

Bourguignon, Lilly Y. W. ;

Gilad, Eli ;

Brightman, Amy ;

Diedrich, Falko ;

Singleton, Patrick .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (20) :14026-14040

[8] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].

Cerami, Ethan ;

Gao, Jianjiong ;

Dogrusoz, Ugur ;

Gross, Benjamin E. ;

Sumer, Selcuk Onur ;

Aksoy, Buelent Arman ;

Jacobsen, Anders ;

Byrne, Caitlin J. ;

Heuer, Michael L. ;

Larsson, Erik ;

Antipin, Yevgeniy ;

Reva, Boris ;

Goldberg, Arthur P. ;

Sander, Chris ;

Schultz, Nikolaus .

CANCER DISCOVERY, 2012, 2 (05) :401-404

[9] Drug development of MET inhibitors: targeting oncogene addiction and expedience [J].

Comoglio, Paolo M. ;

Giordano, Silvia ;

Trusolino, Livio .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) :504-516

[10]

COX DR, 1972, J R STAT SOC B, V34, P187

← 1 2 3 4 5 →